MARKET

ZLAB

ZLAB

Zai Lab
NASDAQ

Real-time Quotes | Nasdaq Last Sale

81.10
+1.40
+1.76%
Pre Market 05:27 07/06 EDT
OPEN
81.48
PREV CLOSE
79.70
HIGH
83.97
LOW
81.03
VOLUME
285.69K
TURNOVER
--
52 WEEK HIGH
83.97
52 WEEK LOW
29.43
MARKET CAP
6.06B
P/E (TTM)
-26.7931
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ZLAB stock price target is 76.11 with a high estimate of 83.00 and a low estimate of 68.00.

EPS

ZLAB News

More
The Daily Biotech Pulse: Eloxx Resumes Cystic Fibrosis Study, Rexahn's Reverse Merger, Ultragenyx, Epizyme Await FDA Decisions
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 17)
Benzinga · 06/18 12:34
Do Hedge Funds Love Zai Lab Limited (ZLAB)?
Insider Monkey · 06/17 19:03
Zai Lab (ZLAB) Investor Presentation - Slideshow
Seeking Alpha - Article · 06/12 20:23
Zai Lab Announces Positive Topline Results from the NORA Phase 3 Study of ZEJULA® as Maintenance Therapy for Chinese Patients with Platinum-sensitive, Recurrent Ovarian Cancer
GlobeNewswire · 05/28 12:37
Zai Lab Announces Presentations at June Conferences
GlobeNewswire · 05/27 12:30
Stocks That Hit 52-Week Highs On Tuesday
During Tuesday's morning trading, 59 companies set new 52-week highs.
Benzinga · 05/19 14:43
The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces $1.34B Common Stock Offering
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 18)
Benzinga · 05/19 12:27
Zai Lab Announces First Chinese Patient Dosed in the Global Phase 3 ATTACK Trial of Sulbactam-Durlobactam for Patients with Carbapenem-Resistant Acinetobacter Infections
Zai Lab Limited (ZLAB), an innovative commercial stage biopharmaceutical company, today announced dosing of the first Chinese patient in the global ATTACK (Acinetobacter Treatment Trial Against Colistin) Phase 3 registrational trial evaluating the combination
GlobeNewswire · 05/18 11:30

Industry

Biotechnology & Medical Research
+0.68%
Pharmaceuticals & Medical Research
+0.61%

Hot Stocks

Symbol
Price
%Change

About ZLAB

Zai Lab Ltd is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with global rights. The greater China rights drug candidates include Niraparib (ZL-2306), Omadacycline (ZL-2401) and ZL-2301. The global rights drug candidates include Fugan (ZL-3101), ZL-2302 and ZL-1101.
More

Webull offers kinds of Zai Lab Ltd stock information, including NASDAQ:ZLAB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZLAB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ZLAB stock methods without spending real money on the virtual paper trading platform.